Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0393754 (HSA)
 2,996 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Dextran sulfate 500 (DS) is known to be a potent B-cell mitogen. Injection of this compound (500 micrograms) into the footpads of mice produced characteristic changes in the draining popliteal lymph nodes, including elimination of macrophages from the lymphatic sinuses and lining the subcapsular sinus, a marked blast reaction throughout the nodal parenchyma, damage to the stroma of the outer peripheral cortex, and disorganization of all the existing primary and secondary lymph follicles. On day 6 after DS treatment, small lymphocytes bearing surface Ig were detected and distributed loosely and broadly in the deeper part of the peripheral cortex without any tendency to reorganize lymph follicles. On day 21, these small lymphocytes populated the outer and deeper layer of the peripheral cortex, sometimes forming nodular accumulations representing regenerating lymph follicles, and on day 35, various numbers of regenerated lymph follicles were present in the peripheral cortex. Tracer studies using FITC-conjugated human serum albumin showed that intraparenchymal diffusion of labeled HSA was highly blocked at the outer peripheral cortex on days 4 through 14, and that this pathway began to reopen at around 21 days. Disorganization of lymph follicles could be considered due to extensive damage to follicle stromata which became unable to bind B lymphocytes, and follicles seem to be re-organized in response to lymph-carried antigen in addition to restored follicle stromata and repopulation B lymphocytes. Macrophages had little effect on the lymph follicle formation in this study.
 ...
PMID:Morphological changes in the mouse popliteal lymph node after local injection of dextran sulfate. 807 29

Splenic malignancies are reported in 30%-76% of dogs presenting with splenic masses, and splenectomy is the cornerstone in their management. However, long term prognosis is guarded due to the high rates of distant metastases reported both for HSA and nonangiogenic nonlymphomatous sarcomas. Metastases from splenic tumors usually occur to regional lymph nodes, liver, omentum, and lungs. These case series aim to describe 2 cases of splenic neoplasia with gastric involvement and report the surgical technique and outcomes associated with the condition. Two mixed-breed dogs were referred for a splenic mass and underwent explorative celiotomy. In both cases, the splenic mass was firmly attached to the gastric wall, and splenectomy with concurrent partial gastrectomy was thus performed. In case 1, liver lobectomy due to a hepatic mass was also performed. In case 2, the regional nodes were also excised due to lymphoadenomegaly. Both dogs recovered uneventfully from surgery and were discharged from the hospital at 72 and 96 hours. Histopathological examination was costent with splenic undifferentiated sarcoma and hepatic adenocarcinoma in one dog. The other dog had a diagnosis of malignant fibrous histiocytoma with nodal metastases. Neoplastic invasion of the stomach was histologically confirmed in both dogs. Adjuvant chemotherapy was refused, and both dogs were euthanized due to tumor progression at 71 and 58 days, respectively. According to our results, splenectomy with concurrent gastrectomy is feasible in dogs with splenic tumours involving the gastric wall. However, long term prognosis is poor, as previously reported for metastatic splenic sarcomas.
 ...
PMID:Partial Gastrectomy at the Time of Splenectomy in Two Dogs With Splenic Neoplasia and Gastric Involvement. 3311 88